Discovery-stage identification of drug-like antibodies using emerging experimental and computational methods
There is intense and widespread interest in developing monoclonal antibodies as therapeutic agents to treat diverse human disorders. During early-stage antibody discovery, hundreds to thousands of lead candidates are identified, and those that lack optimal physical and chemical properties must be de...
Main Authors: | Emily K. Makowski, Lina Wu, Priyanka Gupta, Peter M. Tessier |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2021-01-01
|
Series: | mAbs |
Subjects: | |
Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2021.1895540 |
Similar Items
-
Recent Progress in the Discovery and Development of Monoclonal Antibodies against Viral Infections
by: Pardis Mokhtary, et al.
Published: (2022-08-01) -
Animal immunization merges with innovative technologies: A new paradigm shift in antibody discovery
by: Ponraj Prabakaran, et al.
Published: (2021-01-01) -
Identifying biophysical assays and in silico properties that enrich for slow clearance in clinical-stage therapeutic antibodies
by: Boris Grinshpun, et al.
Published: (2021-01-01) -
Approaches to expand the conventional toolbox for discovery and selection of antibodies with drug-like physicochemical properties
by: Hristo L. Svilenov, et al.
Published: (2023-12-01) -
Therapeutic Application of Monoclonal Antibodies in Pancreatic Cancer: Advances, Challenges and Future Opportunities
by: Gustavo A. Arias-Pinilla, et al.
Published: (2021-04-01)